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Abstract
MC1R is a marker of melanoma risk in populations of European ancestry. However, MC1R effects 
on survival are much less studied. We investigated associations between variation at MC1R and 
survival in an international, population-based series of single primary melanoma patients enrolled 
into the GEM study. MC1R genotype data was available for 2,200 participants with a first incident 
primary melanoma diagnosis. We estimated the association of MC1R genotypes with melanoma-
specific survival (i.e. death due to melanoma) and overall survival using Cox proportional hazards 
modeling, adjusting for established prognostic factors for melanoma. We also conducted stratified 
analyses by Breslow thickness, tumor site, phenotypic index and age. Additionally, we evaluated 
haplotypes involving polymorphisms near the ASIP locus for their impacts on survival. 
Melanoma-specific survival was inversely associated with carriage of MC1R variants in the 
absence of consensus alleles compared to carriage of at least one consensus allele (HR=0.60; 
95%CI: 0.40, 0.90). MC1R results for overall survival were consistent with no association. We did 
not observe any statistical evidence of heterogeneity of effect estimates in stratified analyses. We 
observed increased hazard of melanoma-specific death among carriers of the risk haplotype TG 
near the ASIP locus (HR=1.37; 95%CI: 0.91, 2.04) when compared to carriers of the most 
common GG haplotype. Similar results were noted for overall survival. Upon examining the ASIP 
TG/TG diplotype, we observed considerably increased hazard of melanoma-specific death 
(HR=5.11; 95%CI: 1.88, 13.88) compared to carriers of the most common GG/GG diplotype. Our 
data suggest improved melanoma-specific survival among carriers of two inherited MC1R 
variants.
Introduction
Inherited variation at the melanocortin-1 receptor (MC1R) locus is an established marker of 
elevated melanoma risk in populations of European ancestry 1. However, MC1R effects on 
survival are much less studied. MC1R has pigmentary and non-pigmentary biological 
functions 2, 3, both of which may be important for survival. Studies have shown that carriers 
of red hair color-associated (RHC) MC1R variants are at increased risk of melanoma 1 
possibly due to diminished α-melanocortin mediation of DNA damage repair 4. This 
reduced repair capacity combined with decreased eumelanin may render RHC variant 
carriers more susceptible to the deleterious effects of ultraviolet (UV) radiation 3. 
Juxtaposed against increasing risk for melanoma, it has been suggested that MC1R variants 
confer less resistance to apoptosis and mitigate cell proliferation, thereby improving overall 
survival 5.
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Other pigmentation genes associated with melanoma risk affect MC1R function, and may 
also impact survival. The ASIP locus of chromosome 20, which encodes the agouti signaling 
protein and acts as an antagonist of MC1R directed eumelanin synthesis, has been associated 
with cutaneous phenotype and melanoma risk 6–9. In particular, genome-wide association 
studies demonstrated strong associations between haplotypes composed of polymorphisms 
near the ASIP locus and risk of melanoma 6, 10.
In this study, we evaluate variation at MC1R for associations with melanoma-specific 
survival (i.e. death due to melanoma) and overall survival in a large population-based study 
of melanoma–The Genes, Environment, and Melanoma (GEM) Study. We also investigate 
the impact of a risk haplotype comprising alleles of rs4911414 and rs1015362, which lie 
~110kb upstream of the ASIP locus, on survival. The GEM Study includes individuals with 
a diagnosis of first incident primary invasive melanoma (SPM) recruited from eight 
population-based cancer registries and one hospital-based study in Australia, Canada, Italy, 
and the United States for whom the entire coding region of MC1R was sequenced and two 
single nucleotide polymorphisms (SNPs) near the ASIP locus were genotyped.
Methods
GEM Study
The GEM Study is a population-based case-control study that enrolled a large series of 
individuals diagnosed with a SPM (n=2,424), in addition to 1,206 individuals with an 
incident second or higher order melanoma (MPM). We restrict our focus to SPM cases only 
due to previously reported melanoma risk differences between MPM and SPM with respect 
to MC1R 11. Study participants were identified from eight population-based cancer registries 
and one hospital center in Australia, Canada, Italy and the United States. Details of GEM 
study methodology and procedures relating to study recruitment and survival outcomes have 
been previously described 12–15. The local human research oversight committee approved 
standardized protocol procedures, and signed informed consent was obtained from all 
participants.
Diagnostic pathology reports were obtained for each participant from the appropriate 
ascertainment center, and data corresponding to histological subtype, lesion thickness, and 
anatomic location of lesion were abstracted. Tumor tissue slides for 2,105 (86.8%) 
participants were available for centralized pathological review, performed by one of three 
study pathologists. Standardized pathologic review of slides included evaluation of Breslow 
thickness and presence of ulceration. Since Breslow thickness was both abstracted from the 
pathology report and recorded during the centralized pathologic review, the measure 
corresponding to the deepest reading was chosen to represent the value of most biological 
relevance.
A phenotypic index was derived using data collected from a study participant self-
administered questionnaire 16, and was based on: hair color (black or dark brown=1; light 
brown or blond=2; red=3), eye color (black or brown=0; all other colors=1), and relative 
inability to tan in response to sun exposure (no=0; yes=1) 11. Phenotypic index scores of 1 
and 2 indicate relatively darker cutaneous phenotypes and lower phenotypic melanoma risk; 
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an index score of 3 indicates medium phenotypic risk; and index scores of 4 and 5 indicate 
relatively fairer cutaneous phenotypes and higher phenotypic risks for melanoma.
MC1R and ASIP Genotyping
MC1R and ASIP genotypes were available for 2,200 (90.8%) participants, and we have 
previously reported on genotyping and prevalence of MC1R variants is this study sample 11. 
We adopted nomenclature and definitions based on previous literature 1, 17–20 to classify 
MC1R variants as conferring higher risk for melanoma based on strong association with red 
hair phenotype [R] (D84E, R142H, R151C, R160W, and D294H, all nonsense and insertion/
deletion) or lower risk for melanoma based on weaker association with red hair phenotype 
[r] (all other nonsynonymous variants). Since the exact functional status of many MC1R 
variants is still unknown, we acknowledge that these risk categories may be inaccurate. 
Based on a previous investigation of MC1R and overall survival from cutaneous 
melanoma 5, MC1R genotype was categorized in two ways to assess the relative impacts of 
MC1R variants and consensus (wild type) alleles on survival. Firstly, according to variant 
carriage number: carriage of only consensus alleles versus carriage of only one MC1R 
variant (high- [R] or low- [r] risk) versus carriage of two MC1R variants (high- [R] or low- 
[r] risk); and secondly, by carriage of at least one consensus allele versus carriage of two 
MC1R variants.
Two SNPs comprising a risk haplotype (rs4911414 and rs1015362) 21 located in the 5′-
noncoding region ~110 kb upstream of the ASIP locus were genotyped; rs4911414 was 
genotyped using the Sequenom MassARRAY iPLEX genotyping platform (Sequenom Inc., 
San Diego, CA), with quality control measures implemented as previously described 22 and 
rs1015362 was genotyped as part of a larger panel of SNPs on a custom Illumina 
GoldenGate panel. To ensure quality control of Illumina data, assay intensity data and 
genotype cluster images were evaluated for rs1015362. ASIP haplotypes were constructed 
from participants’ genotype data using the PHASE program v2.1 23, 24 to infer haplotype 
probabilities when genotype data was missing or when genotype phase was ambiguous.
Statistical Analysis
The principal outcome of interest in this study was time from SPM diagnosis to death from 
melanoma, with secondary consideration for time from SPM diagnosis to death by any 
cause. We used Cox proportional hazards modeling via the SAS v9.3 (SAS Institute, Cary, 
NC) PHREG procedure to estimate hazard ratios (HR) and 95% confidence intervals (CI) 
for the association between MC1R genotype or ASIP haplotype and melanoma-specific and 
overall survival, adjusting all models for age at diagnosis, sex, study center, natural log-
transformed Breslow thickness, tumor site (categorized as head/neck, trunk/pelvis, arms, or 
legs), and ulceration. Because a small proportion (4%) of SPM were later ascertained and 
enrolled as a MPM, a dichotomous indicator variable was included in all models to account 
for potential bias introduced by these “crossover” participants.
To evaluate whether MC1R associations with survival outcomes were different across strata 
of selected host and tumor characteristics, we also modeled survival within levels of 
Breslow thickness, tumor site, age at diagnosis, and phenotypic index, and used the Wald 
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test to assess interaction terms. All statistical tests were two-sided with an alpha level of 
0.05.
Results
Table 1 gives overall study characteristics and study characteristics according to survival 
outcomes for our GEM study population. Overall, there were 343 deaths among participants 
with SPM, of which 164 were attributed to melanoma. Median follow-up time was 7.6 years 
(interquartile range, 6.8–7.8).
We observed a statistically significant association between number of MC1R variants and 
hazard of melanoma-specific death (Ptrend=0.04; Table 2). Compared to participants carrying 
only consensus MC1R alleles, there was a muted association among those carrying only a 
single variant (HR=1.13; 95%CI: 0.69, 1.87; Table 2) and an inverse association among 
participants carrying two variants (HR=0.65; 95%CI: 0.38, 1.13; Table 2). Based on these 
results, we categorized the MC1R variable according to carriage of two variants versus 
carriage of any consensus allele, noting a significant inverse association between dual 
variant carriage and hazard of melanoma-specific death (HR=0.60, 95%CI: 0.40, 0.90; Table 
2). Associations of a six-level MC1R variable showing all combinations of r- and R-variants 
and melanoma-specific survival are given in Supplemental Table 1. Observed results for 
overall survival were closer to the null (Supplemental Tables 2 and 3). Utilizing the 
aforementioned dichotomous MC1R variable, we did not observe any statistical evidence of 
heterogeneity of effect estimates across these strata (Table 3); however, we did note isolated 
associations between MC1R and melanoma-specific death within strata of tumor site, age at 
first diagnosis, and phenotypic index. Results of stratified analyses for overall survival were 
similar to those for melanoma-specific survival (Supplemental Table 4).
Haplotype analysis of the ASIP locus suggested increased association between the risk 
haplotype TG--containing the minor allele of rs4911414 and the major allele of rs1015362--
and melanoma-specific survival. Compared to carriage of the most common GG haplotype, 
carriage of TG was associated with poorer melanoma-specific survival (HR=1.37; 95%CI: 
0.92, 2.05), although this association did not attain statistical significance (Table 2). We also 
analyzed ASIP diplotypes (combinations of two-SNP haplotypes) and observed that TG/TG 
was associated with a 5-fold increased hazard of melanoma-specific death when compared 
to carriage of GG/GG (HR=5.10; 95%CI: 1.88, 13.88) (Supplemental Table 5). We did not 
observe any statistical evidence of heterogeneity of haplotype effect estimates within strata 
of Breslow thickness, tumor site, age at first diagnosis, or phenotypic index (Table 3), and 
we saw no clear patterns of association.
Discussion
Results from the GEM Study indicate that melanoma-specific survival among individuals 
with SPM who are lacking a consensus MC1R allele is improved compared to those carrying 
at least one consensus allele. One previous study by Davies et al. 5 assessed the impact of 
inherited MC1R genotype on overall survival among melanoma patients. We directly 
recapitulated their published analysis, which required re-characterizing high and low risk 
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MC1R genotypes using a different classification scheme, recoding covariates, limiting the 
analysis set to GEM participants with thicker (>0.75mm) single primary melanomas, and 
limiting inference to overall survival. Using these filters, carriage of any MC1R variant in 
the absence of consensus alleles indicated better overall survival (HR=0.84; 95%CI: 0.64, 
1.12; data not tabulated) versus carriage of at least one consensus allele in the GEM study. 
This hazard ratio estimate is similar to that of 0.78 (95%CI: 0.65, 0.94) previously reported. 
Although our result was not statistically significant, it is supportive of the meta-analytic 
finding by Davies et al. that was based on a total of 3,060 melanoma cases.
It is an interesting paradox that inherited variation at MC1R increases risk for development 
of melanoma, yet appears to provide a survival advantage to these same individuals. The 
association between MC1R variants and increased risk for melanoma is often discussed in 
terms of decreased eumelanogenesis and the concomitant reduction in protection against the 
known deleterious effects of UV radiation. A plausible alternative mechanism augmenting 
risk among MC1R variant carriers, yet also conferring a survival benefit involves 
pheomelanin synthesis. MC1R variant carriage is associated with higher pheomelanin-to-
eumelanin ratios 25; and murine models have suggested an integral role of pheomelanin in 
normal cell survival and growth by regulating rates of cystine delivery into cells, promoting 
defense against reactive oxygen species 26.
We observed a non-statistically significant modest increased hazard of melanoma-specific 
death among individuals with SPM carrying the TG haplotype composed of alleles from 
SNPs rs4911414 and rs1015362 near the ASIP locus. The risk haplotype has been previously 
reported by Maccioni et al. 21, who noted increased risk of melanoma among carriers 
(OR=1.91; 95%CI: 1.42, 2.57). Assessing the impact of carriage of at least one dual TG 
diplotype carriage on risk of melanoma, they noted a stronger association (OR=2.30; 
95%CI: 1.58, 3.33). Our finding that the ASIP TG/TG diplotype is associated with a 5-fold 
increased hazard of death due to melanoma (HR=5.10; 95%CI: 1.88, 13.85) is consistent 
with the risk finding of Maccioni et al., although we recognize that our HR estimate is based 
on small numbers and is consistent with a smaller effect size. The TG haplotype has also 
been positively associated with fair skin color among Caucasians in the Nurses’ Health 
Study 8, and positively associated with red hair color, freckling, and propensity for sunburn 
among Europeans 27. Although we did not observe any statistically significant difference in 
effect estimates by phenotypic index category, we did notice increasing hazard ratios with 
increasing level of phenotypic index among carriers of TG and a notably strong association 
among the highest index category (Table 3). It is important to note that the SNPs comprising 
the haplotype under investigation do not map to ASIP and are in high LD with a large 
number of variants that map to other biologically plausible loci 21.
The GEM Study relied on death certificate information to verify cause of death, and 
misclassification is a potential concern 28. Although GEM Study centers made every effort 
to ensure accurate ascertainment of participant deaths and causes, it is possible that variation 
in site reporting of death certificate information could have biased our data. While GEM 
benefitted from a robust follow-up time (~7.6 years), we also acknowledge the possibility 
that some melanoma attributed deaths occurred after follow-up ended and were not 
identified.
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The GEM Study is uniquely positioned to investigate the relationship between MC1R and 
survival. The population-based design is a strength in that melanoma survival is likely 
representative of what we might expect in populations of European ancestry. However, the 
population-based nature of GEM also implies that a preponderance of thin or very early 
stage melanomas will be captured (~84% based on SEER data 29), and effects on survival 
might be more easily elucidated in patients with more advanced lesions who are at higher 
risk of melanoma death. We previously examined melanoma tumor characteristics among 
SPM GEM Study participants, and found no evidence to suggest an association between 
AJCC established prognostic factors and MC1R variants (data not published).
In summary, our findings suggest that carriage of MC1R variants in the absence of 
consensus alleles is associated with better melanoma-specific survival among individuals 
with a first incident primary melanoma. In contrast, carriage of the risk haplotype TG near 
the ASIP locus was associated with poor melanoma-specific survival among those same 
individuals.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Study characteristics, melanoma-specific and overall survival among GEM Study single primary melanoma 
cases
Melanoma-specific Overall
N (%a) Deaths (%b) Deaths (%b)
Age
   <40 488 (20) 16 (3) 20 (4)
   40–54 735 (30) 39 (5) 52 (7)
   55–64 451 (18) 35 (8) 51 (11)
   ≥65 794 (32) 74 (9) 220 (28)
Sex
   Male 1278 (52) 112 (9) 240 (19)
   Female 1190 (48) 52 (4) 103 (9)
Center
   British Columbia, Can. 118 (5) 7 (6) 15 (13)
   California, USA 219 (9) 9 (4) 19 (9)
   Michigan, USA 318 (13) 20 (6) 35 (11)
   New Jersey, USA 167 (7) 11 (7) 25 (15)
   New South Wales, Aus. 725 (29) 60 (9) 141 (19)
   North Carolina, USA 285 (12) 10 (4) 29 (10)
   Ontario, Can. 428 (17) 28 (7) 53 (12)
   Tasmania, Aus. 81 (3) 6 (7) 9 (11)
   Torino, Ita. 127 (5) 13 (10) 17 (13)
Body Site
   Trunk/Pelvis 1097 (44) 73 (7) 87 (8)
   Head/Neck 382 (15) 45 (12) 159 (42)
   Arms 460 (19) 21 (5) 53 (12)
   Legs 529 (21) 25 (5) 44 (8)
Ulceration
   No 187 (8) 51 (27) 80 (43)
   Yes 1826 (74) 87 (5) 214 (12)
   missing 455 (18) 26 (6) 49 (11)
Breslow Depth
   0.01–1.00mm 1595 (65) 21 (1) 111 (7)
   1.01–2.00mm 485 (20) 49 (10) 90 (19)
   2.01–4.00mm 228 (9) 51 (22) 80 (35)
   >4.00mm 126 (5) 42 (33) 58 (46)
   missing 34 (1) 1 (3) 4 (12)
Multiple primaries
   No 2372 (96) 152 (6) 322 (14)
   Yes 96 (4) 12 (13) 21 (22)
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a
Column percentages are presented
b
Row percentages are presented
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Table 2
Hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between variation in MC1R and ASIP 
and melanoma-specific survival in GEM Study single primary melanoma cases
Melanoma-specific Survival
MC1R a N (% b) Deaths (% c) HR (95% CI)d
con/con 373 (15) 26 (7) 1.00
r/con, R/con 984 (40) 65 (7) 1.13 (0.69, 1.87)
r/r, r/R, R/R 843 (34) 47 (6) 0.65 (0.38, 1.13)
Missing 268 (11) 26 (10)
Ptrend=0.04
con/con, r/con, R/con 1357 (55) 91 (7) 1.00
r/r, r/R, R/R 843 (34) 47 (6) 0.60 (0.40, 0.90)
Missing 268 (11) 26 (10)
P=0.01
ASIP haplotypese
GG 2927 (57) 211 (7) 1.00
TA 1280 (24) 69 (5) 0.83 (0.60, 1.14)
TG 524 (12) 37 (7) 1.37 (0.92, 2.05)
GA 205 (6) 11 (5) 1.19 (0.60, 2.38)
a
Con=consensus, r=any low risk variant, R=any high risk variant.
b
Column percentages are reported
c
Row percentages are reported
d
Adjusted for age at diagnosis, sex, center, natural log-transformed continuous Breslow thickness, tumor site, ulceration, and multiple melanomas.
e
ASIP haplotype counts represent twice the number of individuals and are estimated by PHASE software assigning the most likely haplotype to an 
individual. HR's and 95% CI's were calculated using haplotype probabilities produced by PHASE, and were modeled in the PHREG procedure of 
SAS v9.3 (SAS Institute, Cary, NC). Haplotypes are inferred from SNPs rs4911414 (G/T) and rs1015362 (G/A).
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